Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post by Luiza Pamela Beato, Medical Oncology Resident, posted on X:
“Biomarker analyses from DB06 presented by Rebecca Dent.
As expected, the benefit of T-DXd over chemo is seen irrespective of tumor genomics (similar to DB04). Most dramatic benefit in the BRCAmut subset, though small numbers and in contrast with other trials (DB03/DB04/RWD).”
More posts featuring ASCO25.